Yan Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yan Zhao has a total of 310 co-authors. Here are the top co-authors by number of shared publications:
- Xiaofeng Zeng
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China
12 shared publications - Wen Zhang
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, The Ministry of Education Key Laboratory, Beijing, China
11 shared publications Xiaofeng Zeng
Key Laboratory of Rheumatology and Clinical Immunology, State Key Laboratory of Complex Severe and Rare Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences and Peking Union Medical College, Ministry of Science and Technology, Ministry of Education, Beijing, China
11 shared publications- Mengtao Li
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China
10 shared publications - Jiuliang Zhao
Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China
8 shared publications Linyi Peng
Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Beijing, China
7 shared publications
Latest Publications
- Open Access
- 28 July 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1839780
Efficacy and safety of Qing Zhu Granules for acute gouty arthritis with dampness-heat obstruction syndrome: study protocol for a phase 3, multicenter, randomized, double-blind, placebo-controlled trial
Although standard therapies for acute gouty arthritis, such as nonsteroidal anti-inflammatory drugs, colchicine, and glucocorticoids demonstrate efficacy, their clinical application is limited by potential adverse reactions, which remains an unresolved issue. Qing Zhu Granules is a traditional Chinese medicine (TCM) compound preparation used for the treatment of primary acute gouty arthritis with dampness-heat obstruction syndrome. This multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trial conducted in China aimed to evaluate the efficacy and safety of Qing Zhu Granules. Patients who met the Western medical diagnostic criteria for gout, met the TCM syndrome differentiation criteria for dampness-heat obstruction syndrome, had an acute attack duration ≤48 h, and a visual analog scale (VAS) score of joint pain ≥ 40 mm in the current attack were included. Participants were randomly assigned in a 1:1 ratio to the Qing Zhu Granules group or the placebo group, with an oral dose of 6 g, administered 3 times a day, for a treatment course of 3 days. During the treatment period, diclofenac sodium enteric-coated tablets could be used as rescue medication in case of intolerable pain. The primary endpoint was the change in joint pain VAS score (0–100 mm) from baseline at 72 h after treatment. The secondary endpoints included changes in joint pain VAS score from baseline at 24 and 48 h after treatment, changes in the total score and each individual item score of the TCM syndrome rating scale from baseline, changes in C-reactive protein levels from baseline at 72 h after treatment, total dose and frequency of rescue medication within 72 h of treatment, and the interval between the first use of rescue medication and the first use of the study drug after treatment initiation. Clinical trial registration: https://clinicaltrials.gov/ , identifier NCT06068478.
- 28 July 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1839780
Open AccessEfficacy and safety of Qing Zhu Granules for acute gouty arthritis with dampness-heat obstruction syndrome: study protocol for a phase 3, multicenter, randomized, double-blind, placebo-controlled trial
Although standard therapies for acute gouty arthritis, such as nonsteroidal anti-inflammatory drugs, colchicine, and glucocorticoids demonstrate efficacy, their clinical application is limited by potential adverse reactions, which remains an unresolved issue. Qing Zhu Granules is a traditional Chinese medicine (TCM) compound preparation used for the treatment of primary acute gouty arthritis with dampness-heat obstruction syndrome. This multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trial conducted in China aimed to evaluate the efficacy and safety of Qing Zhu Granules. Patients who met the Western medical diagnostic criteria for gout, met the TCM syndrome differentiation criteria for dampness-heat obstruction syndrome, had an acute attack duration ≤48 h, and a visual analog scale (VAS) score of joint pain ≥ 40 mm in the current attack were included. Participants were randomly assigned in a 1:1 ratio to the Qing Zhu Granules group or the placebo group, with an oral dose of 6 g, administered 3 times a day, for a treatment course of 3 days. During the treatment period, diclofenac sodium enteric-coated tablets could be used as rescue medication in case of intolerable pain. The primary endpoint was the change in joint pain VAS score (0–100 mm) from baseline at 72 h after treatment. The secondary endpoints included changes in joint pain VAS score from baseline at 24 and 48 h after treatment, changes in the total score and each individual item score of the TCM syndrome rating scale from baseline, changes in C-reactive protein levels from baseline at 72 h after treatment, total dose and frequency of rescue medication within 72 h of treatment, and the interval between the first use of rescue medication and the first use of the study drug after treatment initiation. Clinical trial registration: https://clinicaltrials.gov/ , identifier NCT06068478.
- Open Access
- 20 March 2026
- Published by Elsevier in Autoimmunity Reviews
- Vol. 25 (5) , 104039
Chinese recommendations for the diagnosis and management of non-radiographic axial spondyloarthritis
- 20 March 2026
- Published by Elsevier in Autoimmunity Reviews
- Vol. 25 (5) , 104039
Open AccessChinese recommendations for the diagnosis and management of non-radiographic axial spondyloarthritis
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Immunology Research
- Vol. 2026 (1) , e9771858
Multicenter Analytical Comparison of Automated Quantitative Assays Versus Line Immunoassay for Anti‐Ro/La Antibody Detection in Primary Sjögren’s Syndrome
Objective: This multicenter study aimed to analytically compare the performance of automated quantitative assays—chemiluminescence immunoassay (CLIA) and multiplexed bead immunoassay (MBI)—for detecting anti‐Ro/La antibodies in Chinese patients with primary Sjögren’s syndrome (pSS), compared to line immunoassay (LIA) that is most commonly used in China. Methods: Based on the Chinese Sjögren’s Syndrome Collaborative Research Group, serum samples from 434 patients with pSS and 100 healthy controls were analyzed using LIA, CLIA, and MBI. Sensitivity, specificity, and qualitative agreement were assessed. Receiver operating characteristic (ROC) analysis was carried out to compare the analytical accuracy among assays in detecting anti‐Ro/La antibodies, and the DeLong test was used to compare areas under curves (AUCs). Results: High specificity (95% to 100%) was observed in these assays, and LIA demonstrated the highest sensitivity for anti‐Ro60 (92.6%) and anti‐Ro52 (89.2%). CLIA and MBI exhibited comparable sensitivity to LIA for anti‐La (50.9% vs. 50.2% vs. 48.2%). Qualitative agreement among assays was good for anti‐Ro60 ( κ : 0.84–0.93) and moderate for anti‐La ( κ : 0.74–0.86). MBI achieved the highest AUC values for anti‐Ro60 (0.980), anti‐Ro52 (0.970), and anti‐La (0.935), outperforming CLIA and LIA ( p < 0.05). Conclusion: Automated assays (CLIA and MBI) demonstrate high specificity and analytical accuracy for anti‐Ro/La antibody detection in pSS. MBI achieved the highest accuracy, whereas LIA showed superior sensitivity for anti‐Ro60/52 detection. CLIA provided reliable specificity but failed to detect anti‐Ro52 in this study. Collectively, these findings indicate that CLIA and MBI may represent reliable alternatives to LIA, although validation in disease‐controlled cohorts is required before clinical implementation.
- 1 January 2026
- Published by Wiley in Journal of Immunology Research
- Vol. 2026 (1) , e9771858
Open AccessMulticenter Analytical Comparison of Automated Quantitative Assays Versus Line Immunoassay for Anti‐Ro/La Antibody Detection in Primary Sjögren’s Syndrome
Objective: This multicenter study aimed to analytically compare the performance of automated quantitative assays—chemiluminescence immunoassay (CLIA) and multiplexed bead immunoassay (MBI)—for detecting anti‐Ro/La antibodies in Chinese patients with primary Sjögren’s syndrome (pSS), compared to line immunoassay (LIA) that is most commonly used in China. Methods: Based on the Chinese Sjögren’s Syndrome Collaborative Research Group, serum samples from 434 patients with pSS and 100 healthy controls were analyzed using LIA, CLIA, and MBI. Sensitivity, specificity, and qualitative agreement were assessed. Receiver operating characteristic (ROC) analysis was carried out to compare the analytical accuracy among assays in detecting anti‐Ro/La antibodies, and the DeLong test was used to compare areas under curves (AUCs). Results: High specificity (95% to 100%) was observed in these assays, and LIA demonstrated the highest sensitivity for anti‐Ro60 (92.6%) and anti‐Ro52 (89.2%). CLIA and MBI exhibited comparable sensitivity to LIA for anti‐La (50.9% vs. 50.2% vs. 48.2%). Qualitative agreement among assays was good for anti‐Ro60 ( κ : 0.84–0.93) and moderate for anti‐La ( κ : 0.74–0.86). MBI achieved the highest AUC values for anti‐Ro60 (0.980), anti‐Ro52 (0.970), and anti‐La (0.935), outperforming CLIA and LIA ( p < 0.05). Conclusion: Automated assays (CLIA and MBI) demonstrate high specificity and analytical accuracy for anti‐Ro/La antibody detection in pSS. MBI achieved the highest accuracy, whereas LIA showed superior sensitivity for anti‐Ro60/52 detection. CLIA provided reliable specificity but failed to detect anti‐Ro52 in this study. Collectively, these findings indicate that CLIA and MBI may represent reliable alternatives to LIA, although validation in disease‐controlled cohorts is required before clinical implementation.
- Open Access
- 1 July 2025
- Published by BMJ in Lupus Science & Medicine
- Vol. 12 (2) , e001761
Phenotypically driven subgroups of primary antiphospholipid syndrome-associated thrombocytopenia display distinct outcomes: a prospective cohort study with cluster analysis
Objectives: To identify antiphospholipid antibody-associated thrombocytopenia (aPLs-TP) phenotypes and assess their clinical outcomes. Methods: This single-centre, prospective cohort study (January 2012 to April 2024) consecutively enrolled patients with aPLs-TP from Peking Union Medical College Hospital. Inclusion required persistent aPL positivity (≥12 weeks apart) and platelet (PLT) count 9 /L twice, excluding secondary causes. Demographic aPL profiles and clinical outcomes (thrombosis, pregnancy morbidity, microangiopathy and valve disease) were analysed. Hierarchical clustering and Kaplan-Meier survival analysis were performed. Results: A total of 123 patients (65.9% female, mean age 36.0 years) were consecutively enrolled in the study. Median PLT count was 50.0×10 9 /L. Three clusters were identified: cluster 1 (n=35, all male, median PLT 67.0×10 9 /L) consisted of men with smoking history, hyperhomocysteinaemia and diabetes, demonstrating the highest rate of atherothrombotic and valvular events; cluster 2 (n=51, all female, median PLT 60.0×10 9 /L) included females with recurrent pregnancy morbidity and mild anaemia; and cluster 3 (n=37, 81.1% female, median PLT 27.0×10 9 /L) comprised patients with isolated severe thrombocytopenia with the lowest rate of complete remission. Analysis of event-free survival for key clinical outcomes differed significantly among clusters at 5 years (p=0.026): cluster 1 at 66.9% (95% CI 52.50 to 85.24), cluster 2 at 45.85% (95% CI 32.41 to 64.86) and cluster 3 at 88.68% (95% CI 78.80 to 99.80). Conclusions: Significant heterogeneity exists in patients with aPLs-TP, thus making PLT count alone an inadequate predictor of clinical phenotypes and prognosis. Subgroup analysis leveraging distinct clinical features is essential to develop individualised treatment strategies and improve outcomes.
- 1 July 2025
- Published by BMJ in Lupus Science & Medicine
- Vol. 12 (2) , e001761
Open AccessPhenotypically driven subgroups of primary antiphospholipid syndrome-associated thrombocytopenia display distinct outcomes: a prospective cohort study with cluster analysis
Objectives: To identify antiphospholipid antibody-associated thrombocytopenia (aPLs-TP) phenotypes and assess their clinical outcomes. Methods: This single-centre, prospective cohort study (January 2012 to April 2024) consecutively enrolled patients with aPLs-TP from Peking Union Medical College Hospital. Inclusion required persistent aPL positivity (≥12 weeks apart) and platelet (PLT) count 9 /L twice, excluding secondary causes. Demographic aPL profiles and clinical outcomes (thrombosis, pregnancy morbidity, microangiopathy and valve disease) were analysed. Hierarchical clustering and Kaplan-Meier survival analysis were performed. Results: A total of 123 patients (65.9% female, mean age 36.0 years) were consecutively enrolled in the study. Median PLT count was 50.0×10 9 /L. Three clusters were identified: cluster 1 (n=35, all male, median PLT 67.0×10 9 /L) consisted of men with smoking history, hyperhomocysteinaemia and diabetes, demonstrating the highest rate of atherothrombotic and valvular events; cluster 2 (n=51, all female, median PLT 60.0×10 9 /L) included females with recurrent pregnancy morbidity and mild anaemia; and cluster 3 (n=37, 81.1% female, median PLT 27.0×10 9 /L) comprised patients with isolated severe thrombocytopenia with the lowest rate of complete remission. Analysis of event-free survival for key clinical outcomes differed significantly among clusters at 5 years (p=0.026): cluster 1 at 66.9% (95% CI 52.50 to 85.24), cluster 2 at 45.85% (95% CI 32.41 to 64.86) and cluster 3 at 88.68% (95% CI 78.80 to 99.80). Conclusions: Significant heterogeneity exists in patients with aPLs-TP, thus making PLT count alone an inadequate predictor of clinical phenotypes and prognosis. Subgroup analysis leveraging distinct clinical features is essential to develop individualised treatment strategies and improve outcomes.
- Open Access
- 19 June 2025
- Published by BMJ in Lupus Science & Medicine
- Vol. 12 (1) , e001674
Impact of antiphospholipid antibodies on heart valve involvements in systemic lupus erythematosus: based on CSTAR cohort
Objective: This study aims to evaluate the role of antiphospholipid antibodies (aPLs) in patients with SLE with heart valve diseases (HVDs).Methods: This prospective study included consecutive patients with SLE who visited Peking Union Medical College Hospital between April 1999 and December 2024. Echocardiography was performed based on clinical indications. Clinical characteristics, aPL profiles and echocardiographic findings were collected. Logistic regression was used to evaluate associations between aPLs and HVD.Results: Among 508 patients with SLE, 27.4% had HVD. The most frequently affected valves were aortic (17.3%) and mitral (11.2%) valves, with thickening (19.5%) and regurgitation (15.9%) as the leading lesion types. aPLs positive patients with SLE had higher rates of HVD (35.1% vs 24.0%, p=0.010), including valve thickening (25.3% vs 16.9%, p=0.028), regurgitation (24.7% vs 12.1%, p<0.001), vegetations (9.1% vs 0.8%, p<0.001) and stenosis (1.9% vs 0.0%, p=0.008). Anticardiolipin-IgG was associated with HVD (OR=2.484, p=0.003), mitral lesions (OR=4.156, p<0.001), valve thickening (OR=2.255, p=0.011) and regurgitation (OR=2.121, p=0.014). Anti-β2 glycoprotein I-IgG showed similar associations and was also linked to valve stenosis (OR=11.209, p=0.022). Lupus anticoagulant (LA) was associated with valve vegetations (OR=8.659, p<0.001) and interventional/surgical indications (OR=6.868, p=0.005).Conclusion: aPLs, especially IgG isotype and LA, are independently associated with diverse HVD in SLE. Echocardiographic monitoring is warranted in aPL-positive patients.
- 19 June 2025
- Published by BMJ in Lupus Science & Medicine
- Vol. 12 (1) , e001674
Open AccessImpact of antiphospholipid antibodies on heart valve involvements in systemic lupus erythematosus: based on CSTAR cohort
Objective: This study aims to evaluate the role of antiphospholipid antibodies (aPLs) in patients with SLE with heart valve diseases (HVDs).Methods: This prospective study included consecutive patients with SLE who visited Peking Union Medical College Hospital between April 1999 and December 2024. Echocardiography was performed based on clinical indications. Clinical characteristics, aPL profiles and echocardiographic findings were collected. Logistic regression was used to evaluate associations between aPLs and HVD.Results: Among 508 patients with SLE, 27.4% had HVD. The most frequently affected valves were aortic (17.3%) and mitral (11.2%) valves, with thickening (19.5%) and regurgitation (15.9%) as the leading lesion types. aPLs positive patients with SLE had higher rates of HVD (35.1% vs 24.0%, p=0.010), including valve thickening (25.3% vs 16.9%, p=0.028), regurgitation (24.7% vs 12.1%, p<0.001), vegetations (9.1% vs 0.8%, p<0.001) and stenosis (1.9% vs 0.0%, p=0.008). Anticardiolipin-IgG was associated with HVD (OR=2.484, p=0.003), mitral lesions (OR=4.156, p<0.001), valve thickening (OR=2.255, p=0.011) and regurgitation (OR=2.121, p=0.014). Anti-β2 glycoprotein I-IgG showed similar associations and was also linked to valve stenosis (OR=11.209, p=0.022). Lupus anticoagulant (LA) was associated with valve vegetations (OR=8.659, p<0.001) and interventional/surgical indications (OR=6.868, p=0.005).Conclusion: aPLs, especially IgG isotype and LA, are independently associated with diverse HVD in SLE. Echocardiographic monitoring is warranted in aPL-positive patients.
- Top Cited PapersOpen Access
- 1 May 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (5) , e2511095
Tocilizumab Monotherapy or Combined With Methotrexate for Rheumatoid Arthritis
Importance: Treatment options are needed for patients with rheumatoid arthritis (RA) who experience inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). The efficacy and safety profiles of subcutaneous tocilizumab monotherapy, tocilizumab combined with methotrexate, and methotrexate alone have not yet been evaluated in the same large-scale study.Objective: To evaluate the efficacy and safety of subcutaneous tocilizumab monotherapy, tocilizumab-methotrexate, and methotrexate alone for patients with RA.Design, Setting, and Participants: This double-blind, large-scale phase 3 randomized clinical trial was conducted at 19 sites in China from July 2017 through August 2022, with a 24-week double-blind treatment phase, a 24-week extension phase, and 8 additional weeks of safety follow-up. The trial included adults (aged 18-70 years) who had moderate to severe active RA and had experienced an inadequate response to csDMARDs.Interventions: In the 24-week double-blind treatment phase, patients were randomized 2:2:1 to tocilizumab-methotrexate, tocilizumab-placebo, or methotrexate-placebo. In the 24-week extension phase, patients who achieved a disease activity score using 28 joints (DAS28) of up to 3.2 at week 24 continued their double-blind phase treatment; those with scores greater than 3.2 received open-label tocilizumab-methotrexate. Tocilizumab (162 mg) was administered subcutaneously once every 2 weeks; oral methotrexate (10-25 mg) was administered once weekly.Main Outcomes and Measures: The primary efficacy end point was week 24 American College of Rheumatology 20% improvement (ACR20) response. Long-term efficacy analysis was carried out at week 48; safety was monitored for 56 weeks.Results: This study included 340 patients (mean [SD] age, 47.5 [11.7] years; 294 women [86.5%]). A total of 136 patients were randomized to tocilizumab-methotrexate, 136 to tocilizumab-placebo, and 68 to methotrexate-placebo. The week 24 ACR20 response rate was significantly greater with tocilizumab-methotrexate and tocilizumab-placebo vs methotrexate-placebo (72 of 136 [52.9%] vs 17 of 68 [25.0%]; difference, 27.9 percentage points [95% CI, 14.7-41.2 percentage points]; P < .001; and 68 of 136 [50.0%] vs 17 of 68 [25.0%]; difference, 25.0 percentage points [95% CI, 11.7-38.3 percentage points]; P < .001). The week 48 analysis demonstrated improved or maintained efficacy during the extension period in patients who continued double-blind tocilizumab-placebo or tocilizumab-methotrexate treatment; patients who switched from double-blind tocilizumab-placebo or tocilizumab-methotrexate to open-label tocilizumab-methotrexate had improved disease status. No new safety signals were observed for tocilizumab.Conclusions and Relevance: In this large-scale randomized clinical trial evaluating subcutaneous tocilizumab in Chinese patients, subcutaneous tocilizumab, either as monotherapy or combined with methotrexate, demonstrated superior efficacy to methotrexate monotherapy and was well tolerated. More research data in ethnically and regionally more diverse populations may be needed to further confirm the efficacy and safety of subcutaneous tocilizumab, especially as monotherapy.Trial Registration: ClinicalTrials.gov Identifier: NCT03155347; China Center for Drug Evaluation Identifier: CTR20170141
- 1 May 2025
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 8 (5) , e2511095
Top Cited PapersOpen AccessTocilizumab Monotherapy or Combined With Methotrexate for Rheumatoid Arthritis
Importance: Treatment options are needed for patients with rheumatoid arthritis (RA) who experience inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs). The efficacy and safety profiles of subcutaneous tocilizumab monotherapy, tocilizumab combined with methotrexate, and methotrexate alone have not yet been evaluated in the same large-scale study.Objective: To evaluate the efficacy and safety of subcutaneous tocilizumab monotherapy, tocilizumab-methotrexate, and methotrexate alone for patients with RA.Design, Setting, and Participants: This double-blind, large-scale phase 3 randomized clinical trial was conducted at 19 sites in China from July 2017 through August 2022, with a 24-week double-blind treatment phase, a 24-week extension phase, and 8 additional weeks of safety follow-up. The trial included adults (aged 18-70 years) who had moderate to severe active RA and had experienced an inadequate response to csDMARDs.Interventions: In the 24-week double-blind treatment phase, patients were randomized 2:2:1 to tocilizumab-methotrexate, tocilizumab-placebo, or methotrexate-placebo. In the 24-week extension phase, patients who achieved a disease activity score using 28 joints (DAS28) of up to 3.2 at week 24 continued their double-blind phase treatment; those with scores greater than 3.2 received open-label tocilizumab-methotrexate. Tocilizumab (162 mg) was administered subcutaneously once every 2 weeks; oral methotrexate (10-25 mg) was administered once weekly.Main Outcomes and Measures: The primary efficacy end point was week 24 American College of Rheumatology 20% improvement (ACR20) response. Long-term efficacy analysis was carried out at week 48; safety was monitored for 56 weeks.Results: This study included 340 patients (mean [SD] age, 47.5 [11.7] years; 294 women [86.5%]). A total of 136 patients were randomized to tocilizumab-methotrexate, 136 to tocilizumab-placebo, and 68 to methotrexate-placebo. The week 24 ACR20 response rate was significantly greater with tocilizumab-methotrexate and tocilizumab-placebo vs methotrexate-placebo (72 of 136 [52.9%] vs 17 of 68 [25.0%]; difference, 27.9 percentage points [95% CI, 14.7-41.2 percentage points]; P < .001; and 68 of 136 [50.0%] vs 17 of 68 [25.0%]; difference, 25.0 percentage points [95% CI, 11.7-38.3 percentage points]; P < .001). The week 48 analysis demonstrated improved or maintained efficacy during the extension period in patients who continued double-blind tocilizumab-placebo or tocilizumab-methotrexate treatment; patients who switched from double-blind tocilizumab-placebo or tocilizumab-methotrexate to open-label tocilizumab-methotrexate had improved disease status. No new safety signals were observed for tocilizumab.Conclusions and Relevance: In this large-scale randomized clinical trial evaluating subcutaneous tocilizumab in Chinese patients, subcutaneous tocilizumab, either as monotherapy or combined with methotrexate, demonstrated superior efficacy to methotrexate monotherapy and was well tolerated. More research data in ethnically and regionally more diverse populations may be needed to further confirm the efficacy and safety of subcutaneous tocilizumab, especially as monotherapy.Trial Registration: ClinicalTrials.gov Identifier: NCT03155347; China Center for Drug Evaluation Identifier: CTR20170141
- Open Access
- 10 October 2024
- Published by BMJ in Lupus Science & Medicine
- Vol. 11 (2) , e001244
Clinical features of Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuritis associated with SLE
Objective: We report on the clinical characteristics, treatments and outcomes of Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuritis (CIDP) associated with SLE. Methods: Patients treated at Peking Union Medical College Hospital between January 2004 and November 2021 who fulfilled the diagnostic criteria for SLE and GBS/CIDP (n=9) were included. Clinical presentations, lab results, treatment regimens and prognoses were retrieved and analysed. Results: Six patients were diagnosed with SLE and GBS, while three were diagnosed with SLE and CIDP, with the average age at diagnosis of 38.6±18.2 years. SLE disease duration ranges from 1 week to 36 years, and the courses of GBS and CIDP range from 1 week to 2 months and from 2 months to 15 months, respectively. All patients exhibited either or both limb paresthesia and weakness, other neurological symptoms include dysphagia, peripheral facial nerve palsy and respiratory and cardiac arrest. The median cerebral spinal fluid white blood cell count and protein level were 0.002×109/L (0–0.006×109/L) and 0.79 g/L (0.57–7.09 g/L), respectively. All patients received glucocorticoid and immunoglobulin therapy. Seven patients received cyclophosphamide, and seven patients received intrathecal injections of methotrexate and dexamethasone. Two patients had complete resolution, five experienced marked improvements and two failed to improve with treatments. Conclusion: SLE-associated GBS/CIDP may manifest regardless of disease systemic activity. Clinical features may differ from that of pure GBS/CIDP, and treatment often requires immunosuppressants, making differential diagnosis crucial, especially for patients with GBS/CIDP presenting as the first manifestation of SLE.
- 10 October 2024
- Published by BMJ in Lupus Science & Medicine
- Vol. 11 (2) , e001244
Open AccessClinical features of Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuritis associated with SLE
Objective: We report on the clinical characteristics, treatments and outcomes of Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuritis (CIDP) associated with SLE. Methods: Patients treated at Peking Union Medical College Hospital between January 2004 and November 2021 who fulfilled the diagnostic criteria for SLE and GBS/CIDP (n=9) were included. Clinical presentations, lab results, treatment regimens and prognoses were retrieved and analysed. Results: Six patients were diagnosed with SLE and GBS, while three were diagnosed with SLE and CIDP, with the average age at diagnosis of 38.6±18.2 years. SLE disease duration ranges from 1 week to 36 years, and the courses of GBS and CIDP range from 1 week to 2 months and from 2 months to 15 months, respectively. All patients exhibited either or both limb paresthesia and weakness, other neurological symptoms include dysphagia, peripheral facial nerve palsy and respiratory and cardiac arrest. The median cerebral spinal fluid white blood cell count and protein level were 0.002×109/L (0–0.006×109/L) and 0.79 g/L (0.57–7.09 g/L), respectively. All patients received glucocorticoid and immunoglobulin therapy. Seven patients received cyclophosphamide, and seven patients received intrathecal injections of methotrexate and dexamethasone. Two patients had complete resolution, five experienced marked improvements and two failed to improve with treatments. Conclusion: SLE-associated GBS/CIDP may manifest regardless of disease systemic activity. Clinical features may differ from that of pure GBS/CIDP, and treatment often requires immunosuppressants, making differential diagnosis crucial, especially for patients with GBS/CIDP presenting as the first manifestation of SLE.
- Open Access
- 3 July 2024
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 24 (1) , 1-14
Impact of antiphospholipid antibodies on cardiac valve lesions in systemic lupus erythematosus: a systematic review and meta-analysis
This meta-analysis assesses antiphospholipid antibodies’ (aPLs) impact on heart valve disease in Systemic Lupus Erythematosus (SLE) patients. We searched PubMed, Embase, Cochrane, and Web of Science up to January 2024 for comparative studies of heart valve disease in aPL-positive versus aPL-negative SLE patients. Fixed-effect or random-effect models were used to synthesize data, with I2 and sensitivity analyses for heterogeneity and the trim-and-fill method for publication bias. Including 25 studies with 8089 patients, of which 919 had valvular changes, aPLs significantly increased the risk of heart valve disease (OR = 2.24, 95% CI: 1.58–3.18, p < 0.001). Lupus anticoagulant (LA) indicated the highest risk (OR = 4.90, 95% CI: 2.26–10.60, p < 0.001), anticardiolipin antibodies (aCL) doubled the risk (OR = 2.69, 95% CI: 1.47–4.93, p = 0.001), and anti-β2 glycoprotein I (aβ2GPI) showed a 70% increase (OR = 1.70, 95% CI: 1.17–2.45, p = 0.005). Valve-specific analysis indicated the mitral valve was most commonly involved (26.89%), with higher occurrences in aPL-positive patients (33.34% vs. 15.92%, p = 0.053). Aortic and tricuspid valve involvements were 13.11% vs. 5.42% (p = 0.147) and 12.03% vs. 8.52% (p = 0.039), respectively. Pulmonary valve disease was rare and similar across groups (1.01% in aPL-positive vs. 1.52% in aPL-negative). Significantly, only tricuspid valve disease showed increased risk in aPL-positive patients (OR = 2.66, 95% CI: 1.05–6.75, p = 0.039). APLs notably increase the risk of heart valve disease in SLE patients, with a pronounced effect on tricuspid valve involvement. Regular cardiac assessments for aPL-positive SLE patients are crucial for timely intervention and improved prognosis.
- 3 July 2024
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 24 (1) , 1-14
Open AccessImpact of antiphospholipid antibodies on cardiac valve lesions in systemic lupus erythematosus: a systematic review and meta-analysis
This meta-analysis assesses antiphospholipid antibodies’ (aPLs) impact on heart valve disease in Systemic Lupus Erythematosus (SLE) patients. We searched PubMed, Embase, Cochrane, and Web of Science up to January 2024 for comparative studies of heart valve disease in aPL-positive versus aPL-negative SLE patients. Fixed-effect or random-effect models were used to synthesize data, with I2 and sensitivity analyses for heterogeneity and the trim-and-fill method for publication bias. Including 25 studies with 8089 patients, of which 919 had valvular changes, aPLs significantly increased the risk of heart valve disease (OR = 2.24, 95% CI: 1.58–3.18, p < 0.001). Lupus anticoagulant (LA) indicated the highest risk (OR = 4.90, 95% CI: 2.26–10.60, p < 0.001), anticardiolipin antibodies (aCL) doubled the risk (OR = 2.69, 95% CI: 1.47–4.93, p = 0.001), and anti-β2 glycoprotein I (aβ2GPI) showed a 70% increase (OR = 1.70, 95% CI: 1.17–2.45, p = 0.005). Valve-specific analysis indicated the mitral valve was most commonly involved (26.89%), with higher occurrences in aPL-positive patients (33.34% vs. 15.92%, p = 0.053). Aortic and tricuspid valve involvements were 13.11% vs. 5.42% (p = 0.147) and 12.03% vs. 8.52% (p = 0.039), respectively. Pulmonary valve disease was rare and similar across groups (1.01% in aPL-positive vs. 1.52% in aPL-negative). Significantly, only tricuspid valve disease showed increased risk in aPL-positive patients (OR = 2.66, 95% CI: 1.05–6.75, p = 0.039). APLs notably increase the risk of heart valve disease in SLE patients, with a pronounced effect on tricuspid valve involvement. Regular cardiac assessments for aPL-positive SLE patients are crucial for timely intervention and improved prognosis.
- Open Access
- 12 March 2024
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 26 (1) , 1-7
Antiphospholipid antibodies as potential predictors of disease severity and poor prognosis in systemic lupus erythematosus-associated thrombocytopenia: results from a real-world CSTAR cohort study
Background: To investigate the role of antiphospholipid antibodies (aPLs) in the disease severity and prognosis of SLE-related thrombocytopenia (SLE-TP). Methods: This multicenter prospective study was conducted based on data from the CSTAR registry. TP was defined as a platelet count9/L. Demographic characteristics, platelet count, clinical manifestations, disease activity, and autoantibody profiles were collected at baseline. Relapse was defined as the loss of remission. Bone marrow aspirate reports were also collected. Results: A total of 350 SLE-TP patients with complete follow-up data, 194 (55.4%) were aPLs positive. At baseline, SLE-TP patients with aPLs had lower baseline platelet counts (61.0 × 109/L vs. 76.5 × 109/L, PP9/L vs. 51.0 × 109/L, P = 0.002). In addition, thean increasing number of aPLs types was associated with a decrease in the baseline and minimum values of platelets ( PP = 0.001). During follow-up, SLE-TP carrying aPLs had a higher relapse rate (58.2% vs. 44.2%, P = 0.009) and a lower complete response (CR) rate. As the types of aPLs increased, the relapse rate increased, and the CR rate decreased. Furthermore, there was no significant difference in the ratio of granulocytes to red blood cells (G/E), the total number of megakaryocyte and categories. Conclusion: SLE-TP patients with positive aPLs had more severe disease a lower remission rate but a higher relapse rate.
- 12 March 2024
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 26 (1) , 1-7
Open AccessAntiphospholipid antibodies as potential predictors of disease severity and poor prognosis in systemic lupus erythematosus-associated thrombocytopenia: results from a real-world CSTAR cohort study
Background: To investigate the role of antiphospholipid antibodies (aPLs) in the disease severity and prognosis of SLE-related thrombocytopenia (SLE-TP). Methods: This multicenter prospective study was conducted based on data from the CSTAR registry. TP was defined as a platelet count9/L. Demographic characteristics, platelet count, clinical manifestations, disease activity, and autoantibody profiles were collected at baseline. Relapse was defined as the loss of remission. Bone marrow aspirate reports were also collected. Results: A total of 350 SLE-TP patients with complete follow-up data, 194 (55.4%) were aPLs positive. At baseline, SLE-TP patients with aPLs had lower baseline platelet counts (61.0 × 109/L vs. 76.5 × 109/L, PP9/L vs. 51.0 × 109/L, P = 0.002). In addition, thean increasing number of aPLs types was associated with a decrease in the baseline and minimum values of platelets ( PP = 0.001). During follow-up, SLE-TP carrying aPLs had a higher relapse rate (58.2% vs. 44.2%, P = 0.009) and a lower complete response (CR) rate. As the types of aPLs increased, the relapse rate increased, and the CR rate decreased. Furthermore, there was no significant difference in the ratio of granulocytes to red blood cells (G/E), the total number of megakaryocyte and categories. Conclusion: SLE-TP patients with positive aPLs had more severe disease a lower remission rate but a higher relapse rate.
- 20 September 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (7) , 1917-1922
Effect of smoking on thrombotic antiphospholipid syndrome: a 10-year prospective cohort study
Cigarette smoking is an established risk factor for autoimmune diseases. However, whether smoking plays a clear role in thrombotic antiphospholipid syndrome (TAPS) has not been determined. We aimed to investigate the effects of smoking on clinical characteristics and prognosis of TAPS. This was a prospective cohort study from 2013 to 2022. During the study period, 297 patients were diagnosed with TAPS, including 82 smokers and 215 non-smokers. After propensity score matching, 57 smokers and 57 non-smokers matched by age and sex were analysed. Overall, smokers with TAPS had more cardiovascular risk factors (CVRFs) than non-smokers, including hypertension (36.59% vs. 14.42%, PP=0.029), dyslipidaemia (64.63% vs. 48.37%, P=0.012), and hyperhomocysteinaemia (62.20% vs. 36.28%, PP=0.013), especially myocardial infarction, visceral thrombosis, and peripheral vascular thrombosis. After matching, smokers showed balanced CVRFs with non-smokers at baseline, but retained a higher prevalence of arterial thrombosis (59.65% vs. 33.33%, P=0.005), mainly distributed in cerebral vascular, cardiovascular, and retinal vascular territories. During follow-up, smokers presented a tendency for more recurrent arterial thrombosis and less recurrent venous thrombosis. Smokers had significantly poorer outcomes for organ damage with higher DIAPS (median, 2.00 vs. 1.00, P=0.008), especially in the cardiovascular (26.32% vs. 3.51%, P=0.001), gastrointestinal (15.79% vs. 1.75%, P=0.016), and ophthalmologic (10.53% vs. 00.00%, P=0.027) systems. Smoking is related to increased arterial events and poor prognosis in TAPS patients. Patients with TAPS should be fully encouraged to avoid smoking.
- 20 September 2023
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 63 (7) , 1917-1922
Effect of smoking on thrombotic antiphospholipid syndrome: a 10-year prospective cohort study
Cigarette smoking is an established risk factor for autoimmune diseases. However, whether smoking plays a clear role in thrombotic antiphospholipid syndrome (TAPS) has not been determined. We aimed to investigate the effects of smoking on clinical characteristics and prognosis of TAPS. This was a prospective cohort study from 2013 to 2022. During the study period, 297 patients were diagnosed with TAPS, including 82 smokers and 215 non-smokers. After propensity score matching, 57 smokers and 57 non-smokers matched by age and sex were analysed. Overall, smokers with TAPS had more cardiovascular risk factors (CVRFs) than non-smokers, including hypertension (36.59% vs. 14.42%, PP=0.029), dyslipidaemia (64.63% vs. 48.37%, P=0.012), and hyperhomocysteinaemia (62.20% vs. 36.28%, PP=0.013), especially myocardial infarction, visceral thrombosis, and peripheral vascular thrombosis. After matching, smokers showed balanced CVRFs with non-smokers at baseline, but retained a higher prevalence of arterial thrombosis (59.65% vs. 33.33%, P=0.005), mainly distributed in cerebral vascular, cardiovascular, and retinal vascular territories. During follow-up, smokers presented a tendency for more recurrent arterial thrombosis and less recurrent venous thrombosis. Smokers had significantly poorer outcomes for organ damage with higher DIAPS (median, 2.00 vs. 1.00, P=0.008), especially in the cardiovascular (26.32% vs. 3.51%, P=0.001), gastrointestinal (15.79% vs. 1.75%, P=0.016), and ophthalmologic (10.53% vs. 00.00%, P=0.027) systems. Smoking is related to increased arterial events and poor prognosis in TAPS patients. Patients with TAPS should be fully encouraged to avoid smoking.